Ocular Therapeutix (NASDAQ:OCUL) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Ocular Therapeutix (NASDAQ:OCUL) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a $21.00 price target on the biopharmaceutical company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $30.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, February 5th. TD Cowen reaffirmed a “buy” rating on shares of Ocular Therapeutix in a research note on Thursday, October 30th. HC Wainwright boosted their price target on shares of Ocular Therapeutix from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Monday, December 8th. Needham & Company LLC reissued a “buy” rating and set a $20.00 price objective on shares of Ocular Therapeutix in a report on Monday, December 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, January 22nd. Twelve research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Ocular Therapeutix Price Performance

NASDAQ:OCUL opened at $6.88 on Wednesday. The business’s 50-day simple moving average is $11.04 and its two-hundred day simple moving average is $11.74. Ocular Therapeutix has a 52 week low of $5.78 and a 52 week high of $16.44. The stock has a market cap of $1.50 billion, a PE ratio of -4.78 and a beta of 0.90. The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11.

Ocular Therapeutix (NASDAQ:OCUL) last released its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.04. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The firm had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $16.13 million. During the same quarter last year, the business posted ($0.29) earnings per share. The firm’s revenue was down 22.4% on a year-over-year basis. As a group, analysts forecast that Ocular Therapeutix will post -0.98 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Sanjay Nayak sold 10,348 shares of Ocular Therapeutix stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $9.04, for a total value of $93,545.92. Following the completion of the transaction, the insider owned 332,412 shares in the company, valued at approximately $3,005,004.48. The trade was a 3.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Donald Notman sold 11,446 shares of the firm’s stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $9.04, for a total value of $103,471.84. Following the completion of the sale, the chief operating officer owned 366,356 shares of the company’s stock, valued at approximately $3,311,858.24. This represents a 3.03% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 166,029 shares of company stock valued at $1,498,430. Insiders own 2.30% of the company’s stock.

Institutional Trading of Ocular Therapeutix

A number of hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd grew its holdings in Ocular Therapeutix by 42.5% during the 4th quarter. XTX Topco Ltd now owns 49,073 shares of the biopharmaceutical company’s stock worth $596,000 after acquiring an additional 14,640 shares in the last quarter. Voloridge Investment Management LLC bought a new position in shares of Ocular Therapeutix during the fourth quarter valued at approximately $9,859,000. Wellington Management Group LLP increased its holdings in Ocular Therapeutix by 20.7% during the fourth quarter. Wellington Management Group LLP now owns 74,317 shares of the biopharmaceutical company’s stock valued at $902,000 after buying an additional 12,753 shares during the period. SummitTX Capital L.P. bought a new position in Ocular Therapeutix in the fourth quarter worth approximately $1,149,000. Finally, Twinbeech Capital LP lifted its holdings in Ocular Therapeutix by 123.3% during the fourth quarter. Twinbeech Capital LP now owns 140,350 shares of the biopharmaceutical company’s stock worth $1,704,000 after buying an additional 77,504 shares during the period. 59.21% of the stock is owned by hedge funds and other institutional investors.

More Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 (AXPAXLI) showed statistical superiority on the trial’s primary vision endpoint versus Regeneron’s Eylea in the Phase 3 SOL‑1 study, validating Ocular’s pathway toward an FDA submission and potential commercial opportunity in wet AMD. Ocular Therapeutix’s eye drug superior to Regeneron’s Eylea in late-stage trial
• Positive Sentiment: An analyst reaffirmation and bullish price target — Chardan Capital reissued a “buy” with a $21 target — gives investors a sizable upside thesis should regulatory and commercial questions be resolved. Benzinga
• Neutral Sentiment: Ocular released topline SOL‑1 results and management commentary; while topline reads positive, investors are awaiting full data (subgroup analyses, comparator details, safety, and durability) before repricing longer‑term expectations. Ophthalmology Times
• Negative Sentiment: Market reaction was sharply negative on release day: coverage highlighted the benefit as “modest” and noted that some comparisons used a lower‑dose/less‑favorable Eylea arm, creating doubts about clinical meaningfulness and commercial differentiation. That skepticism appears to have driven heavy selling. MSN article on market reaction
• Negative Sentiment: Significant insider selling was disclosed (including large sales by Pravin Dugel and others, plus Nadia Waheed’s sale), which can amplify downward pressure and signal near‑term insider liquidity actions to the market. SEC filing for insider sales
• Negative Sentiment: Johnson Fistel’s public investor outreach flags an investigation into possible securities claims against Ocular’s officers — news that can increase legal uncertainty and weigh on sentiment until resolved. GlobeNewswire: Johnson Fistel announcement

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.